SCI Abstract

search
+
Synergistic effects of the curcumin analog HO-3867 and olaparib in transforming fallopian tube epithelial cells
Synergistic effects of the curcumin analog HO-3867 and olaparib in transforming fallopian tube epithelial cells
Ovarian cancer remains one of the most lethal gynecologic malignancies, largely due to high recurrence rates and treatment...
Direct functional HOXA9/DNA-binding competitors versus epigenetic inhibitors of HOXA9 expression on cell proliferation, death and differentiation processes in the model of MLL-rearranged acute myeloid leukemia
Direct functional HOXA9/DNA-binding competitors versus epigenetic inhibitors of HOXA9 expression on cell proliferation, death and differentiation processes in the model of MLL-rearranged acute myeloid leukemia
Recent progress in cancer treatment has led to the development of advanced therapies targeting specific oncogenic drivers,...
Anti-CD47 tri-specific killer engager enhances NK cell cytotoxicity against lung cancer
Anti-CD47 tri-specific killer engager enhances NK cell cytotoxicity against lung cancer
Lung cancer remains the leading cause of cancer-related deaths worldwide, with immune evasion posing a major therapeutic c...
Clinical characteristics, treatment and prognosis of pembrolizumab induced myocarditis
Clinical characteristics, treatment and prognosis of pembrolizumab induced myocarditis
To explore the regularity and clinical characteristics of pembrolizumab induced myocarditis, and to provide a reference fo...
The multifaceted role of KIF15 in cancer progression and therapy
The multifaceted role of KIF15 in cancer progression and therapy
Kinesin family member 15 (KIF15), a kinesin superfamily motor protein, is known to be involved in mitotic spindle formatio...
Phase 1/2, open-label study of oral bacterial supplementation (EDP1503) plus pembrolizumab in participants with advanced or metastatic microsatellite-stable colorectal cancer, triple-negative breast cancer, and checkpoint inhibitor–relapsed tumors
Phase 1/2, open-label study of oral bacterial supplementation (EDP1503) plus pembrolizumab in participants with advanced or metastatic microsatellite-stable colorectal cancer, triple-negative breast cancer, and checkpoint inhibitor–relapsed tumors
We report a phase 1/2 study evaluating EDP1503 (capsule containing Bifidobacterium animalis lactis) ± pem...
Tackling tumor hypoxia: advances in breaking the oncogenic HIF-1α–p300/CBP alliance
Tackling tumor hypoxia: advances in breaking the oncogenic HIF-1α–p300/CBP alliance
The ability of tumor cells to survive under low-oxygen conditions is largely attributed to the hypoxia-inducible factor-1 ...
Assessing the risks and benefits of investigational new drugs in adult phase-I oncology trials in China, 2013–2021
Assessing the risks and benefits of investigational new drugs in adult phase-I oncology trials in China, 2013–2021
Previous research shows that the benefits of phase-I oncology trials increased from 5 to 18% between 2000 and 2019 globall...
Beyond the obvious: targeting the SLC transportome and non-canonical drug transport mechanisms in cancer therapy
Beyond the obvious: targeting the SLC transportome and non-canonical drug transport mechanisms in cancer therapy
The solute carrier (SLC) superfamily comprises a broad array of membrane-bound transport proteins that are integral to the...
Clinical potential of antibody–drug conjugates in early-phase clinical trials for late-line treatment of advanced solid tumors
Clinical potential of antibody–drug conjugates in early-phase clinical trials for late-line treatment of advanced solid tumors
Recently, comprehensive genomic profiling (CGP)-matched therapy and antibody–drug conjugates (ADCs) have garnered in...
Sunvozertinib: a Promising Oral EGFR Inhibitor Approved for NSCLC with EGFR Ex20ins Mutations
Sunvozertinib: a Promising Oral EGFR Inhibitor Approved for NSCLC with EGFR Ex20ins Mutations
Lung cancer continues to be a significant health burden in the United States, with 2025 estimates indicating approximately...
Synergistic combination of the adrenergic antagonist SR59230A with common chemotherapeutic drugs and target therapies in cancer and endothelial cells
Synergistic combination of the adrenergic antagonist SR59230A with common chemotherapeutic drugs and target therapies in cancer and endothelial cells
β3-adrenergic receptors (β3-ARs) are increasingly recognized as modulators of tumor progression and treatment re...
The role of dinutuximab beta with beta cell function, apoptosis, and proliferation: new approaches to proteomic analysis of insulinoma
The role of dinutuximab beta with beta cell function, apoptosis, and proliferation: new approaches to proteomic analysis of insulinoma
The aim of this study was to investigate gene expressions related to beta cell function, and the altered protein profiles ...
BRPF1 inhibitor GSK6853 inhibits NSCLC cell proliferation via the JAK2/STAT3/CCNA2 axis to induce cell cycle arrest
BRPF1 inhibitor GSK6853 inhibits NSCLC cell proliferation via the JAK2/STAT3/CCNA2 axis to induce cell cycle arrest
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality worldwide, and current therapies offer...
A phase 2, open-label, single-arm study evaluating the combination of pembrolizumab, lenvatinib, carboplatin and pemetrexed in patients with metastatic non-small cell lung cancer harbouring targetable genomic alterations who progressed on standard tyrosine kinase inhibitors
A phase 2, open-label, single-arm study evaluating the combination of pembrolizumab, lenvatinib, carboplatin and pemetrexed in patients with metastatic non-small cell lung cancer harbouring targetable genomic alterations who progressed on standard tyrosine kinase inhibitors
Patients with metastatic non-small cell lung cancer (NSCLC) harbouring targetable genomic alterations who progressed on st...
Multicenter retrospective study of selpercatinib treatment for advanced or recurrent RET fusion-positive non-small cell lung cancer in Japan
Multicenter retrospective study of selpercatinib treatment for advanced or recurrent RET fusion-positive non-small cell lung cancer in Japan
Selpercatinib is the current standard of care for patients with recurrent or advanced RET fusion-positive non-small cell l...
Phase 1 dose escalation trial of the selective adenosine A2B antagonist PBF-1129 in patients with metastatic non-small cell lung cancer
Phase 1 dose escalation trial of the selective adenosine A2B antagonist PBF-1129 in patients with metastatic non-small cell lung cancer
The adenosinergic pathway represents a critical immunometabolic checkpoint within the tumor microenvironment of non-small ...
and polymorphisms predict sensitivity to first- and third-generation EGFR-TKIs in -mutant NSCLC
and polymorphisms predict sensitivity to first- and third-generation EGFR-TKIs in -mutant NSCLC
This study investigated the association between ATP-binding cassette (ABC) transporter gene polymorphisms and Epidermal Gr...
Ceralasertib, an ATR kinase inhibitor, as monotherapy in Japanese patients with advanced solid malignancies: Results from a phase 1 study
Ceralasertib, an ATR kinase inhibitor, as monotherapy in Japanese patients with advanced solid malignancies: Results from a phase 1 study
Ceralasertib is an oral, selective, and potent inhibitor of ATR serine/threonine kinase, a key protein involved in cell cy...
Clinical features, treatment and outcomes of pembrolizumab induced autoimmune hemolytic anemia
Clinical features, treatment and outcomes of pembrolizumab induced autoimmune hemolytic anemia
To explore the clinical characteristics of pembrolizumab induced autoimmune hemolytic anemia (AIHA) and to provide referen...
Novel GPC3 N-terminal bispecific antibody exhibits dual anti-tumor effect against tumor cells
Novel GPC3 N-terminal bispecific antibody exhibits dual anti-tumor effect against tumor cells
Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide, with poor prognosis and limi...
An investigation of extended-interval dosing of atezolizumab in Japanese patients with advanced solid tumors: safety and pharmacokinetics of a dose of 1680 mg every 4 weeks
An investigation of extended-interval dosing of atezolizumab in Japanese patients with advanced solid tumors: safety and pharmacokinetics of a dose of 1680 mg every 4 weeks
In Japan, atezolizumab is indicated for several cancers at a dose of 1200 mg every 3 weeks or 840 mg eve...
Targeting Myc through BET-PROTAC elicits potent anti-lymphoma activity in diffuse large B cell lymphoma
Targeting Myc through BET-PROTAC elicits potent anti-lymphoma activity in diffuse large B cell lymphoma
Diffuse large B cell lymphoma (DLBCL) presents a great challenge in the clinic due to its poor prognosis. Prior research h...
Safety, tolerability, and preliminary efficacy of nadunolimab, an anti-IL- 1 receptor accessory protein monoclonal antibody, in combination with pembrolizumab in patients with solid tumors
Safety, tolerability, and preliminary efficacy of nadunolimab, an anti-IL- 1 receptor accessory protein monoclonal antibody, in combination with pembrolizumab in patients with solid tumors
Interleukin (IL)-1 signaling has an essential role in tumor progression and immunosuppression and is linked to acquired re...
Unraveling BOLD-100 synergistic potential in pleural mesothelioma treatment: an in vitro study
Unraveling BOLD-100 synergistic potential in pleural mesothelioma treatment: an in vitro study
Pleural mesothelioma (PM) is a rare cancer affecting the pleural layer on the body’s serosal surfaces. Exposure to a...
MicroRNA nanoformulation: a promising approach to anti-tumour activity
MicroRNA nanoformulation: a promising approach to anti-tumour activity
Cancer is a major cause of morbidity and mortality, making it one of the most debilitating diseases in our time. Despite a...
Evaluation of anti-leukemic activity and underlying mechanisms of the novel GSPT1 degrader AB138 in acute myeloid leukemia
Evaluation of anti-leukemic activity and underlying mechanisms of the novel GSPT1 degrader AB138 in acute myeloid leukemia
Acute myeloid leukemia (AML) is a relapsing and drug-resistant hematologic malignancy. We report AB138, a novel molecular ...
TP53 and DNA-PK as potential biomarkers for enhanced efficacy of Olaparib in colorectal cancer
TP53 and DNA-PK as potential biomarkers for enhanced efficacy of Olaparib in colorectal cancer
Olaparib is selected based on the presence of BRCA mutations in patient populations; however, further investigation is sti...
Medulloblastoma associated with Lynch syndrome: a case report of germline variant and tumor molecular characterization
Medulloblastoma associated with Lynch syndrome: a case report of germline variant and tumor molecular characterization
Lynch syndrome (LS) is an autosomal autosomal dominant inherited disease characterized by impaired DNA mismatch repair (dM...
Peptide YY fragment PYY1-36 disrupts mitochondrial biogenesis via RBM43-dependent PGC-1α translation inhibition
Peptide YY fragment PYY1-36 disrupts mitochondrial biogenesis via RBM43-dependent PGC-1α translation inhibition
Mitochondrial dysfunction is a key driver of cancer progression, with therapies increasingly targeting metabolic weaknesse...
Load More
format_indent_increase